Accelerating Drug Discovery with an AI-Based Virtual Human System CODA

Author(s):  
Doheon Lee
2007 ◽  
Vol 6 (4) ◽  
pp. 1-10 ◽  
Author(s):  
Stefan Göbel ◽  
Ido Aharon Iurgel ◽  
Markus Rössler ◽  
Frank Hülsken ◽  
Christian Eckes

This article describes the design of the two application scenarios of the Virtual Human project and its integration into the Virtual Human system. This includes overall concepts and considerations of the demonstrators for the two application scenarios (learning, edutainment) as well as underlying methodic-didactic aspects for knowledge transmission and narrative concepts for story structure and story control during run-time of the system. Hence, in contrast to traditional learning systems with virtual characters as virtual instructors, an exciting and suspenseful interactive information space has been created. On the one hand, the methodic-didactic methods and VH learning model guarantee learning effects, on the other hand narrative structures and an emotion module provide the ground for a playful and exciting story environment, whereby the users can interact and discuss with a set of virtual characters.


Author(s):  
Albert Rizzo ◽  
Belinda Lange ◽  
John G. Buckwalter ◽  
Eric Forbell ◽  
Julia Kim ◽  
...  

2019 ◽  
Author(s):  
Amy Westerling-Bui ◽  
Thomas W. Soare ◽  
Srinivasan Venkatachalan ◽  
Michael DeRan ◽  
Eva Maria Fast ◽  
...  

AbstractA major challenge in drug discovery is gaining confidence in the human relevance of pre-clinical animal studies. While human iPSC-derived organoids offer exciting opportunities to address this, concerns about applicability and scalability remain. Here, we report a high-throughput organoid platform for assessment of kidney disease targeting compounds in a human system. We confirmed platform reproducibility by single cell RNA-Seq (scRNA-Seq) and derived a NanoString panel for efficient quality control (QC). Organoid transplantation in rats for 2 to 4 weeks promoted organoid maturation and vascularization. In functional studies, cyclosporine A (CsA) and GFB-887, a novel TRPC5 channel blocker, protected kidney organoids from injury. Pharmacodynamic studies with GFB-887 delivered orally to rats were also successfully performed in human transplanted organoids. These data show how human organoids can deliver confidence in taking development candidate compounds to the clinic, fulfilling their promise to revolutionize drug discovery.


Sign in / Sign up

Export Citation Format

Share Document